Compare Entergy Corporation (ETR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entergy Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Entergy Corporation trades at $103.92 (market cap $50.16B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Entergy Corporation is far larger — about 6.7× Spyre Therapeutics Inc. Common Stock's market cap, and Entergy Corporation pays a 2.44% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entergy Corporation for 13 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ETR | SYRE | |
|---|---|---|
Market Cap | $50.16B | $7.52B |
Volume | 2,603,991 | 1,441,031 |
Sector | Utilities | Health |
52-Week High | $117.91 | $108.92 |
52-Week Low | $91.19 | $22.18 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $80.94B | $6.52B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entergy Corporation (ETR) trades at $104.99, up 0.96% with a bullish technical signal despite overbought RSI readings. The stock shows strong fundamentals with 13.48% net margins and consistent earnings beats in recent quarters. Recent developments include $13.7M in federal grid funding and new data center agreements benefiting customers. Analyst consensus remains strongly positive with 59% buy ratings and a $123.17 price target representing 17% upside potential.
ETR presents a compelling investment case with stable utility operations, improving cash flows, and strategic grid investments. However, elevated valuation multiples and institutional selling activity warrant caution. The stock's proximity to resistance at $105 suggests near-term consolidation may precede further gains if earnings momentum continues through Q3 results.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entergy Corporation
Entergy is an energy company that operates regulated electric utilities and power generation businesses in the United States. Its generation portfolio includes nuclear, natural gas, and renewable resources.
Read more on ETR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
